Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083803 | 1.00 | HSD17B10 (0.54) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6744121 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| Tetraxetan SCHEMBL2635294 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3503521 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| Tetraxetan SCHEMBL18018 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| Tetraxetan SCHEMBL2017956 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6848102 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL321989 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL173508 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3660521 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | HSD17B10 3503/4885SLC6A9 4782/4885S1PR1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.